Lexaria Bioscience (LEXX) Liabilities and Shareholders Equity (2011 - 2026)

Lexaria Bioscience has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $4.8 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 29.07% year-over-year to $4.8 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $21.5 million (down 36.93% YoY) and the FY2025 annual result came in at $4.2 million, down 52.92% from the prior year.
• Liabilities and Shareholders Equity retreated to $4.8 million in Q2 2026 per LEXX's latest filing, from $6.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $11.4 million in Q1 2022 and troughed at $114546.0 in Q1 2023.
• A 5-year average of $5.2 million and a median of $5.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity soared 8214.68% in 2022, then sank 99.0% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $118096.0 in 2022, then climbed by 12.3% to $132627.0 in 2023, then jumped by 7284.45% to $9.8 million in 2024, then plunged by 38.22% to $6.1 million in 2025, then dropped by 20.98% to $4.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $4.8 million, $6.5 million, and $6.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.